Dr. Hye Sook Chon, MD

Dr. Chon practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Chon's NPI, 1619102563, was assigned on May 21, 2009. Dr. Chon graduated from Kyung Hee University College of Medicine in 1997. Dr. Chon holds Florida license ME103590.

Dr. Chon's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Chon's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Chon is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Chon to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chon practices, 3 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Chon's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Chon is board certified in gynecologic oncology by the American Board of Obstetrics and Gynecology. Dr. Chon is licensed in Florida.

Dmand AI lists abdominal adhesion surgery, hysterectomy and menopause among the conditions Dr. Chon treats.

CMS data shows 124 Medicare services from Dr. Chon across 2 procedure codes in 2024, all of them office visits, for 100 Medicare patients. Medicare paid $11,716 for them.

CMS counts 100 Medicare patients who saw Dr. Chon in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chon's median patient age at 65, with 99% women.

In 2024, Dr. Chon wrote 90 Medicare Part D claims for 38 patients. 88% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $32 in total drug cost. In 2022, CMS named 60 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Chon for performance year 2024, reported as part of a group. Dr. Chon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chon as offering telehealth. CMS counts 12 procedures of removal of the uterus by Dr. Chon, more than 86% of the clinicians it reports for that procedure.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 558 papers to Dr. Chon, published from 2011 to 2025. 2023 was the busiest year, with 175. The most frequent topics are Odorants, Perfume and Consumer Product Safety. Dr. Chon has published most often in Food Chem Toxicol. Dr. Chon's most frequent co-authors are Ingi Lee, MD, Robert M. Wenham, MD and Sachin Apte, MD.

Dmand AI links Dr. Chon to 11 clinical trials, 7 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Ovarian Neoplasms and Ovarian Diseases. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 39 general payments to Dr. Chon from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Eisai Inc. paid the most, $19,508.

Dr. Chon graduated from Kyung Hee University College of Medicine in 1997.

Dr. Chon is in network with 9 carriers, including Excellus BlueCross BlueShield, Blue Cross Blue Shield of Michigan and Humana. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.